Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma

Feng, Lingxin; Wang, Jing; Yu, Zhuang; Song, Shanai; Zhai, Wenxin; Dong, Shenghua; Yu, Hongwen; Zhang, Y.

doi:10.1007/s12094-018-02014-6

Cited by 18 publications

(19 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Advanced LUAD is a heterogeneous and complex disease with poor prognosis. However, due to the discovery of EGFR tyrosine kinase inhibitors, EGFR mutation subgroup shows longer progression free disease rate and over survival rate than EGFR-WT subgroup (14).Furthermore, serum tumor markers have been proven associated with EGFR mutation status and e cacy of EGFR-TKI treatment in lung cancer (15) However, there is no a consensus regarding appropriate tumor markers to distinguish the prognosis and e cacy of EGFR-TKI in advanced LUAD patients with different EGFR status. Herein, we screened and identi ed that CA153 and Cyfra21-1 was a prognostic marker in EGFR-mutant LUAD patient,coincide with CA125 in EGFR-WT LUAD group.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Prognostic and Predictive Value of Pretreatment Serum Tumor Markers in Lung Adenocarcinoma with Different EGFR Status

Chen¹,

Li²,

Yan³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The prognostic value of carcinoembryonic antigen (CEA), cytokeratin-19 fragments (Cyfra21-1), neuron-specific enolase (NSE), Glycogen Antigen 153, Glycogen Antigen 199 has been investigated in Lung Adenocarcinoma (LUAD). However, few studies have directly focused on the association between serum tumor markers and epidermal growth factor receptor (EGFR) mutation status.Material and Method: 146 patients with stage IIIB and IV LUAD were enrolled between 2008 and 2018. Correlations between serum tumor marker levels, EGFR mutations and survival were analyzed and prognostic factors were identified.Result: Of eligible 90 patients with EGFR-mutant LUAD, CA 15-3 (7 versus 9 months, 0.037 for PFS; 25 months versus 36 month, P = 0.003 for OS, ) and Cyfra21-1 (7.0 versus 9.0 months, P =0.010 for PFS, 25 months versus 36 months, P=0.044 for OS,showed negatively significant correlation with overall survival and Progression free survival. For parents without EGFR-mutation, CA125 (month versus 8 months, P = 0.013 for DFS, 18 months versus 24 month, P = 0.016 for OS) also showed negatively significant correlation with overall survival and Progression free survival.Conclusion: CA153 and Cyfra21-1 was a prognostic serum biomarker in EGFR-mutant LUAD patient, coincide with CA125 in EGFR-WT LUAD group.Cyfra21-1 levels was also a predictive serum biomarker for in EGFR-mutant LUAD patient who received EGFR-TKI treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

“…PR 13 15.85% were SD, 30(36.59%) were PD respectively. PR and SD were de ned as effective while PD were regard as ineffective.…”

mentioning

confidence: 94%

The Prognostic and Predictive Value of Pretreatment Serum Tumor Markers in Lung Adenocarcinoma with Different EGFR Status

Chen¹,

Li²,

Yan³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Therefore, it is necessary to improve the method to increase the positive detection rate of bacteria in pleural effusion. cfDNA is disintegrating DNA from cells and pathogens in the process of apoptosis or dying, which can be shed into body fluids, including blood, cerebrospinal fluid, urine, pleural, and ascites (16)(17)(18)(19)(20)(21)(22)24). Therefore, in theory, the cfDNA of pathogens in pleural effusion is not affected even if antibiotics are used.…”

Section: Discussionmentioning

confidence: 99%

“…cfDNA can be detected in pleural effusion, ascites, urine, prostatic fluid, synovial fluid, cerebrospinal fluid, and blood (16,17). The study on free DNA discovered mature blood of tumor patients, while cfDNA can be used as an index for early detection, diagnosis, and later targeted drug use (17)(18)(19)(20)(21). In recent years, cfDNA has been found in the body fluids of patients infected with some pathogens, including Plasmodium, parasites, and Mycobacterium tuberculosis (22)(23)(24)(25)(26).…”

Section: Introductionmentioning

confidence: 99%

Detection of Klebsiella pneumoniae cfDNA in pleural fluid and its clinical value

Ren

Chu

et al. 2020

Ann Palliat Med

View full text Add to dashboard Cite

Background: Klebsiella pneumoniae (KP) is an important opportunistic pathogen that can easily cause pneumonia and pleural effusion when body resistance is reduced. However, the positive rate of KP detected from clinical pleural effusion by traditional methods, including bacterial culture, is meager. Therefore, new detection methods are urgently needed to improve the positive detection rate of KP and other bacteria in pleural effusion.Methods: Simulated pleural fluid of KP infection was first set up. Then circulating cell-free DNA (cfDNA) was extracted from cultured hydrothorax and detected by fluorescence polymerase chain reaction (PCR) to verify KP cfDNA in the pleural fluid. The specificity, sensitivity, and repeatability of this method are verified by detecting the cfDNAs in pleural effusion, samples of malignant pleural effusion, tuberculous pleural effusion, and other common microbial infections. Finally, this method was compared with three traditional methods, pleural effusion, precipitation DNA, sputum culture, and pleural effusion culture to explore the clinical diagnostic value of this method.Results: KP cfDNA was positive by fluorescence PCR from the simulated KP infected pleural effusion, which confirmed KP cfDNA in pleural effusion. KP cfDNA was positive by fluorescence PCR from the pleural effusion of KP infected patients, while with the same detection method, KP cfDNA in clinical carcinomatous hydrothorax, tuberculosis hydrothorax, and other standard microbial infection samples was negative, which confirmed the method had high specificity, high sensitivity, and reproducibility. Compared with the three traditional methods, this method has a higher positive rate. Compared with the gold standard, sputum bacterial culture, the sensitivity, specificity, positive predictive value, and negative predictive value of this method were 91.67%, 95.45%, 91.7%, and 95.5%, respectively. Conclusions:The detection of cfDNA by fluorescence PCR is possible. Moreover, the positive rate of this method in clinical pleural effusions is high.

show abstract

“…Lung cancer is the leading cause of cancer-related mortality worldwide and is associated with an overall 5-year survival rate lower than 16% 1–4. Non-small cell lung carcinoma (NSCLC) accounts for approximately 75–85% of the total number of lung cancers, of which adenocarcinoma is the main subtype 5,6. Most cases of lung adenocarcinoma, often without obvious clinical symptoms at the early diagnosis, are generally diagnosed with locally advanced or metastatic diseases 7.…”

Section: Introductionmentioning

confidence: 99%

<p>THAP7 promotes cell proliferation by regulating the G1/S phase transition via epigenetically silencing p21 in lung adenocarcinoma</p>

Chen

Sang

Liu

et al. 2019

OTT

View full text Add to dashboard Cite

Purpose Lung adenocarcinoma (LUAD) is one of the most common cancers worldwide. The THanatos-Associated Proteins (THAP) family plays an essential role in multiple cancers. However, the role of THAP7 in cancers has remained elusive. Methods THAP7 expression status in LUAD tissues was analysed by using the Oncomine database and qRT-PCR, and its expression level in LUAD cell lines was detected by qRT-PCR and Western blotting. The role of THAP7 in LUAD cells was determined by proliferation, colony formation, and cell cycle analyses. In vivo role of THAP7 was studied on xenograft models. Luciferase reporter assays and chromatin immunoprecipitation (ChIP) were used to determine the activity and acetylation of the p21 promoter. Results THAP7 expression was increased in LUAD tissues and cell lines. Moreover, the high expression of THAP7 was correlated with poor prognosis. The overexpression of THAP7 accelerated the G1/S phase transition and promoted tumour growth both in vitro and in vivo. A mechanistic study revealed that THAP7 reduced the acetylation of histone H3 on the p21 promoter to suppress p21 transcription. Conclusion For the first time, we demonstrated the function of THAP7 in LUAD, and our findings suggested that THAP7 may be a potential molecular therapy target in LUAD.

show abstract

Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma

Cited by 18 publications

References 43 publications

The Prognostic and Predictive Value of Pretreatment Serum Tumor Markers in Lung Adenocarcinoma with Different EGFR Status

The Prognostic and Predictive Value of Pretreatment Serum Tumor Markers in Lung Adenocarcinoma with Different EGFR Status

Detection of Klebsiella pneumoniae cfDNA in pleural fluid and its clinical value

<p>THAP7 promotes cell proliferation by regulating the G1/S phase transition via epigenetically silencing p21 in lung adenocarcinoma</p>

Contact Info

Product

Resources

About